It was found that the AT and RT of VX2 tumors in the NAFLD group were significantly reduced, and no significant differences in the general characteristics of the tumors in the two groups, including size, morphology, blood flow signals, and immunohistochemical markers MVD, VEGF, Ki67, and PCNA. Here, VEGFA is linked to metabolic dysfunction-associated steatotic liver disease.